{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"26","value":"220.6"},{"groupId":"OG001","spread":"65","value":"257.6"},{"groupId":"OG002","spread":"30","value":"213.7"},{"groupId":"OG003","spread":"22","value":"219.8"},{"groupId":"OG004","spread":"31","value":"178.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"22"}],"units":"Participants"}],"title":"Avelumab Cycle 1/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"51","value":"54.00"},{"groupId":"OG001","spread":"50","value":"42.66"},{"groupId":"OG002","spread":"45","value":"49.85"},{"groupId":"OG003","spread":"35","value":"50.86"},{"groupId":"OG004","spread":"33","value":"47.68"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"23"}],"units":"Participants"}],"title":"Avelumab Cycle 1/Day8-168 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23","value":"241.9"},{"groupId":"OG001","spread":"17","value":"240.3"},{"groupId":"OG002","spread":"33","value":"228.7"},{"groupId":"OG003","spread":"29","value":"235.5"},{"groupId":"OG004","spread":"68","value":"180.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"20"}],"units":"Participants"}],"title":"Avelumab Cycle 1/Day15-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22","value":"242.8"},{"groupId":"OG001","spread":"18","value":"256.2"},{"groupId":"OG002","spread":"27","value":"277.1"},{"groupId":"OG003","spread":"22","value":"249.1"},{"groupId":"OG004","spread":"22","value":"188.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"20"}],"units":"Participants"}],"title":"Avelumab Cycle 2/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19","value":"223.9"},{"groupId":"OG001","spread":"44","value":"204.1"},{"groupId":"OG002","spread":"10","value":"254.4"},{"groupId":"OG003","spread":"31","value":"184.9"},{"groupId":"OG004","spread":"21","value":"205.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"11"}],"units":"Participants"}],"title":"Avelumab Cycle 4/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"comment":"Geometric Coefficient of Variation was not estimable as there was only 1 participant analyzed.","groupId":"OG001","spread":"NA","value":"143.0"},{"groupId":"OG003","spread":"18","value":"280.6"},{"groupId":"OG004","spread":"110","value":"137.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"title":"Avelumab Cycle 6/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"comment":"Geometric Coefficient of Variation was not estimable as there was only 1 participant analyzed.","groupId":"OG003","spread":"NA","value":"231.0"},{"groupId":"OG004","spread":"13","value":"197.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"}],"units":"Participants"}],"title":"Avelumab Cycle 10/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21","value":"6413"},{"groupId":"OG001","spread":"25","value":"21560"},{"groupId":"OG002","spread":"13","value":"74090"},{"groupId":"OG003","spread":"28","value":"6919"},{"groupId":"OG004","spread":"37","value":"6085"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"23"}],"units":"Participants"}],"title":"PF- 04518600 Cycle 1/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"51","value":"2669"},{"groupId":"OG001","spread":"25","value":"9427"},{"groupId":"OG002","spread":"34","value":"31650"},{"groupId":"OG003","spread":"32","value":"3131"},{"groupId":"OG004","spread":"28","value":"2631"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"23"}],"units":"Participants"}],"title":"PF-04518600 Cycle 1/Day8-168 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"77","value":"5969"},{"groupId":"OG001","spread":"24","value":"27460"},{"groupId":"OG002","spread":"22","value":"96640"},{"groupId":"OG003","spread":"71","value":"6697"},{"groupId":"OG004","spread":"35","value":"7173"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"19"}],"units":"Participants"}],"title":"PF-04518600 Cycle 1/Day15-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33","value":"7776"},{"groupId":"OG001","spread":"16","value":"31880"},{"groupId":"OG002","spread":"56","value":"104100"},{"groupId":"OG003","spread":"30","value":"9212"},{"groupId":"OG004","spread":"25","value":"7627"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"23"}],"units":"Participants"}],"title":"PF-04518600 Cycle 2/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43","value":"8792"},{"groupId":"OG002","spread":"20","value":"155000"},{"groupId":"OG003","spread":"61","value":"11730"},{"groupId":"OG004","spread":"36","value":"10180"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"12"}],"units":"Participants"}],"title":"PF-04518600 Cycle 4/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"comment":"Geometric Coefficient of Variation was not estimable as there was only 1 participant analyzed.","groupId":"OG001","spread":"NA","value":"32000"},{"groupId":"OG003","spread":"27","value":"14020"},{"groupId":"OG004","spread":"10","value":"9753"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"title":"PF-04518600 Cycle 6/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG003","spread":"16","value":"14060"},{"groupId":"OG004","spread":"18","value":"10660"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"}],"units":"Participants"}],"title":"PF-04518600 Cycle 10/Day1-1 Hour/EOI"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"23"}],"units":"Participants"}],"description":"Cmax is maximum observed plasma concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"During Phase 1b participants received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.","id":"OG000","title":"Combination B Phase 1b: PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 1b participants received PF-04518600 1.0 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.","id":"OG001","title":"Combination B Phase 1b: PF-04518600 1.0 mg/kg + Avelumab"},{"description":"During Phase 1b participants received PF-04518600 3.0 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.","id":"OG002","title":"Combination B Phase 1b: PF-04518600 3.0 mg/kg + Avelumab"},{"description":"During Phase 2 participants with NSCLC received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W.","id":"OG003","title":"Combination B Phase 2 NSCLC: PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 2 participants with SCCHN received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W.","id":"OG004","title":"Combination B Phase 2 SCCHN: PF-04518600 0.3 mg/kg + Avelumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) analysis set included all participants who had received at least one dose of study drug and who had at least one of the PK concentrations of interest for Avelumab, Utomilumab, PD 0360324, PF-04518600. Here, \"Number of participants analyzed'' signifies number of participants evaluable for this outcome measure, where \"Number Analyzed\" signifies number of participants evaluable for specified time points.","reportingStatus":"POSTED","timeFrame":"1-hour post-dose on Day 1,15 of Cycle 1; Day 8 of Cycle 1 (non-dosing); Day 1 of Cycle 2, 4, 6 and Cycle 10","title":"Maximum Observed Plasma Concentration (Cmax) of Avelumab and PF-04518600 in Combination B","type":"SECONDARY","unitOfMeasure":"Nanogram per milliliter"}